TrialInvestigational new drugs2023

An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer.

Jayanthi Vijayakumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.